Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis

Arthritis Rheum. 2000 Jan;43(1):195-205. doi: 10.1002/1529-0131(200001)43:1<195::AID-ANR24>3.0.CO;2-G.

Abstract

Objective: To correlate the increased collagenase production previously seen in chondrocytes isolated from osteoarthritic (OA) lesions and the expression of cytokines and cytokine receptors.

Methods: Chondrocytes were isolated from OA cartilage and characterized for synthesis of collagenases, cytokines, and cytokine receptors by Northern and Western blot analyses, RNA protection assay, and flow cytometry.

Results: Chondrocytes located in cartilage proximal to the macroscopic OA lesions bound more tumor necrosis factor alpha (TNFalpha) and interleukin-1beta (IL-1beta) compared with chondrocytes isolated from morphologically normal cartilage from the same joint. In response to TNFalpha stimulation, messenger RNA (mRNA) levels for the IL-1 receptor I (IL-1RI), IL-1RII, TNF receptor II (TNFR II), and IL-6 receptor as well as the level of proinflammatory cytokines, such as IL-1alpha, IL-1beta, lymphotoxin beta, TNFalpha, and IL-6, also increased. In contrast, treatment with transforming growth factor beta1 (TGFbeta1) resulted in down-regulation of matrix metalloproteinase 1 (MMP-1) and MMP-13 concomitant with a reduction in the levels of mRNA for IL-1RI, IL-1RII, TNFRI, and TNFRII and proinflammatory cytokine levels. In contrast, the levels of mRNA for TGFbeta receptor I, TGFbeta1, and TGFbeta3 were up-regulated.

Conclusion: These data show that TGFbeta1 has antagonistic effects upon OA chondrocytes, in contrast to the effects seen with TNFalpha. The cyclical course of OA, where a period of active disease is followed by a period of remission, can be explained by a sequential pattern of cytokine stimulation followed by a feedback inhibition of autocrine cytokine production and cytokine receptor expression, thus affecting collagenase synthesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Autocrine Communication / immunology*
  • Chondrocytes / enzymology*
  • Chondrocytes / immunology
  • Collagenases / analysis
  • Collagenases / genetics
  • Collagenases / metabolism*
  • Flow Cytometry
  • Gene Expression Regulation, Enzymologic / immunology*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / genetics
  • Interleukin-1 / metabolism
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Matrix Metalloproteinase 1 / analysis
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase 1 / metabolism
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinases / analysis
  • Matrix Metalloproteinases / genetics
  • Matrix Metalloproteinases / metabolism*
  • Middle Aged
  • Osteoarthritis / immunology
  • Osteoarthritis / metabolism*
  • Phenotype
  • RNA, Messenger / analysis
  • Receptors, Interleukin-1 / genetics
  • Receptors, Interleukin-1 Type II
  • Receptors, Interleukin-6 / genetics
  • Receptors, Tumor Necrosis Factor / genetics
  • Sialoglycoproteins / genetics
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta / pharmacology
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Interleukin-6
  • RNA, Messenger
  • Receptors, Interleukin-1
  • Receptors, Interleukin-1 Type II
  • Receptors, Interleukin-6
  • Receptors, Tumor Necrosis Factor
  • Sialoglycoproteins
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Collagenases
  • MMP13 protein, human
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 1